CONMED to Announce Third Quarter 2025 Results on November 5: What Investors Should Expect
CONMED Corporation (NYSE: CNMD), a global medical technology company specializing in surgical devices and equipment, has confirmed that it will release its financial results for the third quarter of 2025 on Wednesday, November 5, 2025. The company will publish its earnings after the U.S. financial markets close, followed by a management-hosted conference call at 4:30 p.m. Eastern Time to discuss performance highlights and answer questions from analysts and investors.
This announcement comes at a critical time not only for CONMED, but also for the broader medical technology industry, which continues to navigate a shifting healthcare landscape shaped by hospital capital spending trends, global demand for surgical solutions, supply chain challenges, and evolving reimbursement dynamics. Investors, analysts, and healthcare stakeholders will be tuning in closely to gain insights into how CONMED is performing in this environment and how it is positioning itself for the quarters ahead.
Headquartered in Largo, Florida, CONMED is a well-established player in the global medical technology sector. The company focuses on the development, manufacturing, and distribution of surgical devices and equipment that are widely used in hospitals, ambulatory surgery centers, and specialty clinics worldwide.
Its product portfolio spans multiple surgical specialties, including:
- Orthopedic surgery – minimally invasive arthroscopy products, sports medicine implants, and powered surgical instruments.
- General surgery – advanced energy solutions, electrosurgical devices, and surgical visualization systems.
- Laparoscopic and gastrointestinal procedures – instruments and systems used in minimally invasive interventions.
With a presence in over 100 countries and a workforce numbering in the thousands, CONMED has consistently emphasized innovation and global market penetration. Its mission is to improve patient outcomes and enable surgeons to deliver high-quality care through reliable, cutting-edge devices.
Why This Earnings Report Matters
Quarterly earnings reports are pivotal for publicly traded companies, offering shareholders and the investment community a snapshot of recent performance, strategic execution, and near-term outlook. For CONMED, the third quarter of 2025 may be particularly significant given:
- Medtech Sector Dynamics – The medical technology industry has been experiencing both tailwinds and headwinds. On one hand, rising demand for elective procedures has fueled growth in surgical device utilization as patient volumes recover from pandemic-era slowdowns. On the other, hospitals face tight capital budgets, and inflationary pressures remain a factor.
- Competition – CONMED operates in highly competitive markets, going head-to-head with larger players such as Medtronic, Johnson & Johnson (Ethicon), and Stryker. Analysts will be watching whether the company has been able to expand market share or defend margins against pricing pressures.
- Innovation Pipeline – The company has historically relied on innovation to drive differentiation. Updates around new product launches or adoption trends could influence investor confidence in CONMED’s long-term growth trajectory.
- International Expansion – With a significant portion of sales generated outside the United States, fluctuations in currency exchange rates and international demand are likely to impact reported results.
Key Metrics to Watch in Q3 2025
When CONMED releases its third-quarter earnings, stakeholders will be paying close attention to a number of financial and operational metrics, including:
- Revenue Growth – Investors will look for topline momentum in core business segments, particularly orthopedic and general surgery devices.
- Operating Margins – Cost control and efficiency initiatives will be key to offsetting inflationary pressures.
- Earnings per Share (EPS) – A critical measure of profitability that signals how effectively management is generating value for shareholders.
- Cash Flow and Debt Management – As a capital-intensive company, CONMED’s ability to manage debt and generate cash for reinvestment will be an important focus.
- Geographic Performance – Growth in emerging markets versus established regions such as North America and Europe will provide insight into the company’s diversification strategy.
The Conference Call: A Deeper Dive into Strategy
Management will host its third-quarter 2025 earnings call at 4:30 p.m. ET on November 5. Investors can register to participate via telephone by following pre-registration instructions provided on the company’s website.
For those unable to join by phone, CONMED will webcast the conference call through the “Investors” section of its website at The webcast replay will be made available approximately one hour after the call’s conclusion, allowing interested parties to revisit management’s commentary at their convenience.
Earnings calls are often more than a review of numbers—they are an opportunity for executives to outline strategic priorities, address headwinds, and provide guidance for the upcoming quarter and fiscal year. For CONMED, topics that may feature prominently include:
- The adoption trajectory of newly launched surgical devices.
- Updates on supply chain and manufacturing capabilities.
- Trends in hospital capital spending and the impact on product demand.
- The role of artificial intelligence and digital health technologies in surgical care.
- Ongoing efforts to enhance shareholder value through operational discipline.
Medtech Industry
The medtech sector remains a cornerstone of the global healthcare system, driven by demographic shifts such as an aging population, increased prevalence of chronic diseases, and growing demand for minimally invasive procedures. At the same time, healthcare providers are increasingly focused on cost-effectiveness and value-based care, placing pressure on device manufacturers to deliver innovation that improves outcomes while managing costs.
For companies like CONMED, this creates both challenges and opportunities:
- Challenges: Rising input costs, intense competition, reimbursement uncertainty, and global regulatory complexity.
- Opportunities: Strong procedure growth, especially in orthopedic and gastrointestinal surgery, and expansion into high-growth markets in Asia-Pacific, Latin America, and the Middle East.
Investor Sentiment Ahead of the Call
In the weeks leading up to earnings season, analysts typically release previews or updates that shape market expectations. While CONMED has not provided pre-announcements for Q3, Wall Street will likely benchmark its results against broader medtech peers to evaluate relative performance.
Some analysts may be optimistic that demand for elective surgeries will continue to bolster results, while others may highlight ongoing headwinds such as hospital budget pressures and supply chain constraints. The earnings release and subsequent call will provide clarity on which factors dominated the company’s performance in Q3 2025.
